OakChart

Kala Bio Inc

KALAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:57 PM ET

0.17100.0000 (0.00%)
2026-11-12 04:13 CET
Market cap
3.31 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-10.08 USD m
Free cash flow, TTM
-19.86 USD m
EPS diluted, TTM
-73.93
P/E
-
Compare

Price

KALA against its 20, 50 and 200-day averages
2050200beat
0.0050.00100.00150.0019.0M37.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26KALAclose 0.1720-day 0.1850-day 0.35200-day 5.600.1752w high

99.8% under the 52-week high of 95.50 on 1 Dec 2025. 52-week low 0.12 on 14 Oct 2026. Last 15 sessions, 33.3% high to low

Volume 0.07× normal · the line is the 50-bar volume average

Profile

KALA
52-week range, 0% of the way up
0.1195.50

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Employees6
IPOJul 20, 2017
Beta-2.20
ATR, 14d0.03
Rel volume0.07
Short float2.06%
Insider own3.89%
Inst own3.73%

Snapshot

6 groups

Valuation

Index-
Market Cap3.31M
Enterprise Value-3.92M
Income-10.08M
Sales0.00M
Book/sh0.47
Cash/sh0.37
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOJul 20, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.37
P/C0.46
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.88
Current Ratio6.88
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-73.93
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y51.75% 49.38%
Sales past 3/5Y- -
EPS Y/Y TTM78.25%
Sales Y/Y TTM-
EPS Q/Q75.10%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.-0.39% -

Ownership

Insider Own3.89%
Insider Trans0.00%
Inst Own3.73%
Inst Trans9.14%
ROA-43.23%
ROE-345.32%
ROIC-111.46%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.91%
SMA50-50.86%
SMA200-96.94%
Trades-

Technical

Shs Outstand19.34M
Shs Float18.59M
Short Float2.06%
Short Ratio0.25
Short Interest0.38M
52W High95.50 -99.82%
52W Low0.11 49.21%
Volatility12.04% 16.34%
ATR (14)0.03
RSI (14)30.62
Beta-2.20
Rel Volume0.07
Avg Volume1.50M
Volume105,445

Performance

Perf Week-3.99%
Perf Month-34.23%
Perf Quarter-81.49%
Perf Half Y-94.41%
Perf YTD-99.38%
Perf Year-99.54%
Perf 3Y-99.94%
Perf 5Y-100.00%
Perf 10Y-
Recom3.00
Target Price1250.00
Prev Close0.17
Price0.17
Change %0.00%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 30, 2025DowngradeMMizuhoOutperform → Neutral$1.50+777.2%
Sep 29, 2025DowngradeLLadenburg ThalmannBuy → Neutral
Sep 29, 2025DowngradeHH.C. WainwrightBuy → Neutral
Sep 08, 2025InitiatedMMizuhoOutperform$30+17,443.9%
Jul 11, 2025InitiatedLLadenburg ThalmannBuy$12+6,917.5%
Mar 30, 2022DowngradeJJP MorganNeutral → Underweight
Aug 06, 2021DowngradeJJP MorganOverweight → Neutral
Sep 14, 2020DowngradeJJefferiesBuy → Hold$10+5,748.0%
Jul 23, 2020InitiatedNNorthland CapitalOutperform
Jun 01, 2020ResumedOOppenheimerOutperform$21+12,180.7%

Peers

Mkt cap
TickerCompanyMkt cap
KPRXKiora Pharmaceuticals Inc5.98M
KLRSKalaris Therapeutics Inc41.50M
BFRGBullfrog AI Holdings Inc10.76M
OKYOOKYO Pharma Limited74.52M
CDIOCardio Diagnostics Holdings Inc5.68M
SKYESkye Bioscience Inc4.06M
ENVBEnveric Biosciences Inc6.67M
MGRXMangoceuticals Inc4.42M
LFMDLifeMD Inc85.80M

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
ANDREW I KOVENDirectorMar 17 '26Proposed Sale0.2614,4663,816Mar 17 04:21 PM
Howard B RosenDirectorMar 12 '26Proposed Sale0.2913,5763,975Mar 12 05:40 PM
CHARLES D MYERSDirectorMar 12 '26Proposed Sale0.319,1122,858Mar 12 04:04 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2025Q42026-11-09--16.0001.232--1
2025Q32025-11-17-50.500-50.500-53.7030.000.001
2025Q22025-08-08-85.500-85.167-85.5000.000.003
2025Q12025-05-14-70.500-101.5-70.4950.000.002
2024Q42025-03-31-87.000-114-87.0680.000.002
2024Q32024-11-12-96.500-121.5-96.7030.000.002
2024Q22024-08-06-158-220.25-158.060.000.002
2024Q12024-05-14-210-144.5-209.850.000.002
2023Q42024-03-29-159-181-159.030.000.003
2023Q32023-11-13-170.5-149-170.650.002.501
2023Q22023-08-04-218-159.34-218.050.000.003
2023Q12023-05-09-349.5-242.34-349.290.000.003
2022Q42023-03-03-398.5-327.75-1,3910.000.002
2022Q32022-11-08962.5537.5962.430.4262.502
2022Q22022-08-11-950-1,088-953.852.102.022
2022Q12022-05-16-1,125-841.08-1,1181.373.115

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-6,236-5,509-6,2360.000.00
2019FY-6,900-6,700-6,8956.077.77
2020FY-4,975-4,614-4,9806.366.43
2021FY-5,475-4,395-5,46811.2412.58
2022FY-1,474-1,189-1,4743.893.76
2023FY-867.5-901.67-867.580.000.00
2024FY-507.5-541.75-507.50.000.00
2025FY--222.5-165.56-0.00
2026FY--26.500--0.00
2027FY--20.000---
2028FY--9.000---
2029FY--8.500---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q4S2025-10-201000.000.000.00
2025Q4S2025-09-052000.000.000.00
2025Q4S2025-08-081000.000.000.00
2025Q4S2025-05-141000.000.000.00
2025Q4S2025-03-311000.000.000.00
2025Q4S2025-01-051000.000.000.00
2025Q4S2025-01-041000.000.000.00
2025Q4S2025-01-031000.000.000.00
2025Q4S2025-01-021000.000.000.00
2025Q4S2025-01-011000.000.000.00
2025Q4S2024-12-311000.000.000.00
2025Q4S2024-12-301000.000.000.00
2025Q4S2024-12-291000.000.000.00
2025Q4S2024-12-281000.000.000.00

Estimate history

EPS, annual-9277.15-6236.275-6894.75-4979.575-5467.75-1473.816-867.576-507.252-165.557-73.9271
Period201720182019202020212022202320242025TTM
EPS, quarterly-158.058-96.703-87.068-70.495-85.635-53.7031.232-0.137-21.319
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual006.0746.36211.243.8920000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.010.0140.0140.0240.0260.0340.0550.1220.55719.34
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0920.0920.1220.1290.1340.1490.55718.5919.34
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.003.8911.246.366.070.00
Cost of Goods Sold Incl. D&A0.180.320.260.302.564.103.172.850.95
Gross Profit-0.18-0.32-0.26-0.301.337.143.193.23-0.95
Selling, General and Administrative Excl. Other24.2342.0940.1738.8582.69116.5899.4291.4563.77
Research and Development6.4318.4621.8418.5917.6511.5218.3526.9629.29
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-24.41-42.41-40.43-39.15-81.36-109.43-96.23-88.22-64.72
Interest Expense1.103.285.785.817.278.388.598.483.31
Unusual Expense-9.21-9.040.550.512.9324.900.000.000.39
Net Income Before Taxes-10.08-26.98-38.51-42.20-44.82-142.60-104.33-94.35-66.74
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-10.08-26.98-38.51-42.20-44.82-142.60-104.33-94.35-66.74
Net Income From Continuing Operations-10.08-26.98-38.51-42.20-44.82-142.60-104.33-94.35-66.74
Net Income-10.08-26.98-38.51-42.20-44.82-142.60-104.33-94.35-66.74
EPS (Recurring)-222.91-204.39-502.19-860.24-1,406.31-4,799.55-4,979.57-6,894.74-6,210.78
EPS (Basic, Before Extraordinaries)-73.93-165.56-507.25-867.58-1,473.82-5,467.75-4,979.57-6,894.75-6,236.27
EPS (Diluted)-73.93-165.56-507.25-867.58-1,473.82-5,467.75-4,979.57-6,894.75-6,236.27
EBITDA-24.23-42.09-40.17-38.85-80.50-107.17-93.39-85.61-63.77
Non-Operating Income (Expense)6.229.668.263.2846.730.100.492.361.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.847.008.397.467.0116.0913.319.998.62
Price To Sales Ratio----14.917.0255.8220.78-
Gross Margin----34.2263.5550.1353.11-
Operating Margin-----2,090.34-973.60-1,512.59-1,452.49-
Net Margin-----1,151.64-1,268.73-1,639.85-1,553.29-
Shares Outstanding19.340.560.120.060.030.030.020.010.01
Market Capitalization3.313.3142.2718.8556.3379.18399.05133.03165.43

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.050.130.070.070.070.06
Gross Profit0.000.00-0.05-0.13-0.07-0.07-0.07-0.06
Selling, General and Administrative Excl. Other1.721.8010.1710.5310.8110.589.399.51
Research and Development0.060.060.316.006.175.995.195.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.72-1.80-10.22-10.66-10.88-10.65-9.46-9.57
Interest Expense0.000.000.140.961.081.091.391.48
Unusual Expense0.000.00-5.79-3.420.150.020.000.42
Net Income Before Taxes-1.58-1.620.69-7.56-11.15-8.95-8.18-8.95
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.58-1.620.69-7.56-11.15-8.95-8.18-8.95
Net Income From Continuing Operations-1.58-1.620.69-7.56-11.15-8.95-8.18-8.95
Net Income-1.58-1.620.69-7.56-11.15-8.95-8.18-8.95
EPS (Recurring)-21.32-0.14-6.05-70.71-84.81-70.38-87.07-93.53
EPS (Basic, Before Extraordinaries)-21.32-0.141.23-53.70-85.64-70.49-87.07-96.70
EPS (Diluted)-21.32-0.141.23-53.70-85.64-70.49-87.07-96.70
EBITDA-1.72-1.80-10.17-10.53-10.81-10.58-9.39-9.51
Non-Operating Income (Expense)0.140.185.260.640.952.812.682.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.14-0.470.402.042.242.312.092.04
Shares Outstanding19.3418.590.560.150.130.130.120.09
Market Capitalization3.31160.9015.4811.3731.7936.9742.2726.28

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.5651.1850.9070.5094.18153.5485.45170.90114.56
Short Term Receivables0.000.000.246.5017.459.8513.101.030.00
Inventories0.000.000.000.008.645.234.654.090.00
Other Current Assets1.931.621.748.954.092.762.291.010.65
Total Current Assets9.4952.8052.8785.94124.37171.38105.48177.03115.21
Net Property, Plant & Equipment0.002.442.780.424.0231.0232.482.170.79
Total Investments and Advances0.000.250.300.461.4612.9912.5812.210.13
Intangible Assets0.000.000.000.00---29.570.41
Other Assets0.000.000.000.009.586.223.780.000.00
Total Assets9.4955.4855.9586.82139.43221.61154.32220.97116.55
Short Term Debt Incl. Current Port. of LT Debt0.0010.720.335.010.711.531.330.467.06
Accounts Payable0.990.630.922.352.781.722.525.451.20
Other Current Liabilities1.515.617.0918.3233.9318.9720.9311.106.61
Total Current Liabilities2.4916.968.3525.6837.4222.2324.7717.0114.87
Long Term Debt0.0021.5435.9937.9479.4899.3999.8698.9811.99
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.004.664.114.225.720.000.000.000.01
Total Liabilities2.4943.1548.4567.85122.62121.61124.63115.9926.87
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity7.0012.337.5018.9716.80100.0029.69104.9889.68
Total Shareholders Equity7.0012.337.5018.9716.80100.0029.69104.9889.68
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity7.0012.337.5018.9716.80100.0029.69104.9889.68
Total Liabilities & Stockholders Equity9.4955.4855.9586.82139.43221.61154.32220.97116.55
Book Value Per Share12.56101.23135.97555.78641.374,243.162,057.027,750.189,136.63
Tangible Book Value Per Share12.56101.23135.97555.78641.374,243.162,057.025,567.429,094.55
Full-Time Employees638433419218813613037
Price to Book Ratio0.373.431.68-58.204.713.994.481.584.55
Return on Assets-83.05-69.12-59.12-39.62-79.00-55.50-50.28-39.60-51.83
Return on Equity-279.18-388.29-318.75-250.56-244.19-160.89-140.12-68.57-70.17
Return on Invested Capital-385.65-113.71-97.02-78.76-148.11-52.33-72.83-32.72-41.52
Quick Ratio3.813.116.333.353.097.484.0710.177.75
Current Ratio3.813.116.333.353.327.714.2610.417.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.08-26.98-38.51-42.20-44.82-142.60-104.33-94.35-66.74
Depreciation0.180.320.260.470.982.312.842.620.95
Other Funds (Non Cash)-3.930.1910.654.90-35.5542.6814.3710.959.28
Funds from Operations-13.82-26.47-27.60-36.82-79.40-97.62-87.12-80.78-56.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-6.04-5.52-1.788.890.49-10.62-3.57-11.942.38
Cash from Operating Activities-19.86-31.99-29.38-27.93-78.91-108.23-90.69-92.72-54.12
Capital Expenditures0.00-0.01-0.21-0.61-0.31-0.89-1.94-1.33-1.58
Net Assets From Acquisitions0.000.000.000.000.00-4.650.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.0563.020.090.000.00-
Purchase or Sale of Investments-7.000.000.000.130.0176.25-76.270.000.00
Purchase of Investments-7.000.000.00-9.87-4.990.00-113.590.000.00
Sale Or Maturity of Investments0.000.000.0010.005.0076.2537.330.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-7.00-0.01-0.21-0.4362.7270.80-78.21-1.33-1.58
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock15.1010.8922.7620.5532.1042.82160.669.0171.30
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock15.1010.8922.7620.5532.1042.82160.669.0171.30
Proceedsfrom Stock Options15.0210.8122.6820.5031.8041.23158.568.4370.77
Issuance or Reduction of Debt, Net-20.00-22.507.24-10.00-40.04-0.26-0.03-0.0352.81
Change in Long Term Debt-20.00-22.507.24-10.00-40.04-0.26-0.03-0.0352.81
Issuance of Long Term Debt0.000.0012.280.000.0077.780.000.0052.81
Reduction of Long Term Debt-20.00-22.50-5.04-10.00-40.04-78.05-0.03-0.030.00
Net Financing Active Other Cash Flow0.060.00-0.12-2.040.000.000.000.000.00
Other Financing Activities Uses0.060.00-0.12-2.040.000.000.000.000.00
Cash from Financing Activities-4.85-11.6229.888.51-7.9442.55160.638.98124.10
Net Change in Cash-31.71-43.620.29-19.85-24.135.12-8.28-85.0768.41
Free Cash Flow-19.86-32.01-29.59-28.54-79.22-109.12-92.64-94.06-55.70
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.238.767.5621.1031.9442.22
Short Term Receivables0.210.070.000.010.132.47
Inventories0.000.000.000.000.000.00
Other Current Assets3.143.481.933.171.591.02
Total Current Assets10.5812.329.4924.2733.6645.72
Net Property, Plant & Equipment0.000.000.000.602.162.30
Total Investments and Advances0.000.000.000.140.230.24
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets10.5812.329.4925.0236.0548.25
Short Term Debt Incl. Current Port. of LT Debt0.000.000.0028.839.9215.90
Accounts Payable1.141.040.990.920.660.93
Other Current Liabilities0.400.511.512.835.446.15
Total Current Liabilities1.541.562.4932.5716.0222.98
Long Term Debt0.000.000.001.1120.0116.45
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.003.233.12
Total Liabilities1.541.562.4933.6939.2642.54
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity9.0410.767.00-8.66-3.215.71
Total Shareholders Equity9.0410.767.00-8.66-3.215.71
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity9.0410.767.00-8.66-3.215.71
Total Liabilities & Stockholders Equity10.5812.329.4925.0236.0548.25
Book Value Per Share0.470.5812.56-58.29-24.0044.23
Tangible Book Value Per Share0.470.5812.56-58.29-24.0044.23
Full-Time Employees--6---
Price to Book Ratio0.3714.952.21-1.31-9.926.48
Return on Assets-43.23-64.90-83.05-90.62-76.24-70.40
Return on Equity-345.32-238.68-279.18--708.34-576.46
Return on Invested Capital-17.48-15.069.81--66.37-40.37
Quick Ratio6.887.913.810.752.101.99
Current Ratio6.887.913.810.752.101.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.58-1.620.69-7.56-11.15-8.95
Depreciation0.000.000.050.130.070.07
Other Funds (Non Cash)-0.141.28-3.91-1.172.662.61
Funds from Operations-1.72-0.34-3.17-8.60-8.43-6.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.18-2.56-1.39-2.270.69-2.55
Cash from Operating Activities-1.53-2.90-4.56-10.88-7.73-8.82
Capital Expenditures0.000.000.000.00-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00-7.000.000.000.000.00
Purchase of Investments0.00-7.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-7.000.000.00-0.020.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock0.004.1010.930.060.00-0.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.004.1010.930.060.00-0.11
Proceedsfrom Stock Options0.004.1010.93-0.010.00-0.11
Issuance or Reduction of Debt, Net0.000.00-20.000.00-2.500.00
Change in Long Term Debt0.000.00-20.000.00-2.500.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-20.000.00-2.500.00
Net Financing Active Other Cash Flow0.000.000.09-0.03-0.03-0.03
Other Financing Activities Uses0.000.000.09-0.03-0.03-0.03
Cash from Financing Activities0.004.10-8.980.03-2.53-0.14
Net Change in Cash-1.53-5.79-13.54-10.85-10.28-8.96
Free Cash Flow-1.53-2.90-4.56-10.88-7.75-8.82

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.06%0.4M18.6M1.49M
2026-10-152.90%0.5M18.6M1.48M
2026-09-307.31%1.4M18.6M1.39M
2026-09-152.40%0.4M18.6M342.21K
2026-08-312.17%0.4M18.6M171.54K
2026-08-141.37%0.3M18.6M134.49K
2026-07-311.51%0.3M18.6M138.15K
2026-07-151.44%0.3M17.8M131.90K
2026-06-301.23%0.2M17.8M104.67K
2026-06-150.35%0.1M18.6M82.62K
2026-05-290.38%0.1M18.6M170.04K
2026-05-150.23%0.0M18.6M161.26K
2026-04-300.11%0.0M18.6M150.51K
2026-04-150.11%0.0M18.6M141.63K
2026-03-310.13%0.0M17.1M142.26K
2026-03-130.80%0.1M17.1M134.74K
2026-02-270.11%0.0M17.1M151.55K
2026-02-132.51%0.0M0.5M161.93K
2026-01-302.26%0.0M0.5M159.61K
2026-01-151.68%0.0M0.5M156.41K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-19SCHEDULE 13GSEC
2026-09-24DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-03SEC
2026-09-11PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-11SEC
2026-09-108-KCurrent report2026-09-03SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-288-KCurrent report2026-08-27SEC
2026-08-1910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14NT 10-Q2026-06-30SEC
2026-07-238-KCurrent report2026-07-22SEC
2026-07-22424B5SEC
2026-07-02SCHEDULE 13D/ASEC
2026-06-25EFFECTEffectiveness filing by commission orderSEC
2026-06-12S-3/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-07S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-078-KCurrent report2026-05-07SEC
2026-03-31NT 10-K2025-12-31SEC
2026-03-17144Filing for proposed sale of securities under Rule 144.SEC
2026-03-17DNotice of sales of securities on Form D (Regulation D)SEC
2026-03-12144Filing for proposed sale of securities under Rule 144.SEC
2026-03-12144Filing for proposed sale of securities under Rule 144.SEC
2026-03-048-KCurrent report2026-03-03SEC
2026-02-208-KCurrent report2026-02-16SEC
2026-02-17EFFECTEffectiveness filing by commission orderSEC
2026-02-17424B3SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-13CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC1.19%
GEODE CAPITAL MANAGEMENT, LLC0.90%
VANGUARD FIDUCIARY TRUST CO0.55%
STATE STREET CORP0.48%
BlackRock, Inc.0.38%
NORTHERN TRUST CORP0.22%
Qube Research & Technologies Ltd0.06%
GOLDMAN SACHS GROUP INC0.06%
UBS Group AG0.01%
Tower Research Capital LLC0.00%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.19%
Fidelity Extended Market Index Fund0.50%
Fidelity Series Total Market Index Fund0.13%
Fidelity Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.07%

OakChart. KALA. Cached 15 minutes.